Attention Deficit/Hyperactivity Disorder (ADHD)Phase 1NCT07098585
To Compare and Evaluate the Oral Bioavailability of Lisdexamfetamine 70 mg Capsule With That of Elvanse® 70 mg Capsules, Hard Lisdexamfetamine Dimesylate in Healthy, Adult, Human Subjects Under Fasting Conditions.
A Phase 1 study testing Lisdexamfetamine capsule and Elvanse® (Lisdexamfetamine dimesylate capsules, hard) in people with Attention Deficit/Hyperactivity Disorder (ADHD), run by Humanis Saglık Anonim Sirketi at 1 site in India.
Trial summary
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Attention Deficit/Hyperactivity Disorder (ADHD)
- What is being tested?
- Lisdexamfetamine capsule and Elvanse® (Lisdexamfetamine dimesylate capsules, hard)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 48 participants
- Where
- 1 siteIndia
- Study dates
- 26 May 2025to 17 Jul 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age: 18 to 55 years old, both inclusive.
- Gender: Male and/or non-pregnant, non-lactating female.
- Female of child-bearing potential had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days of the first dose of study medication. They used an acceptable form of contraception. For female of child-bearing potential, acceptable forms of contraception included the following:
- Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.
- Female was not considered of child-bearing potential if one of the following was reported and documented on the medical history:
- Postmenopausal with spontaneous amenorrhea for at least one year, or ii. Spontaneous amenorrhea for more than 6 months and less than one year with Serum Follicular Stimulating Hormone (FSH) level > 40 mIU/mL, or iii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or iv. Total hysterectomy and an absence of bleeding for at least 3 months.
Show all 11Show fewer
- BMI: 18.5 to 30.0 kg/m2, both inclusive; BMI value was rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
- Non-smokers and non-tobacco user (i.e. had no past history of smoking and tobacco consuming for at least one year prior to study).
- Able to communicate effectively with study personnel.
- Willing to provide written informed consent to participate in the study.
- All volunteers were assessed as normal and healthy by the principal investigator, co-investigator, or physician during the pre-study safety assessment conducted within 28 days of the first dose of study drug.
Who cannot join
- History of allergic responses to Lisdexamfetamine Dimesylate, sympathomimetic amines or other related drugs, or any of its formulation ingredients.
- Had significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, ECG recording, echocardiography, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
- Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
- History or presence of bronchial asthma.
- Used any hormone replacement therapy within 3 months prior to the first dose of study medication.
- Used any depot injection or implant of any drug within 3 months prior to the first dose of study medication.
Show all 26Show fewer
- Used CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication.
- History or evidence of drug dependence or of alcoholism or of moderate alcohol use.
- History of difficulty with donating blood or difficulty in accessibility of veins.
- A positive hepatitis screen (includes subtypes B \& C).
- A positive test result for HIV antibody.
- Volunteers who had received a known investigational drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
- Volunteers who had donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever was greater.
- History of difficulty in swallowing or of any gastrointestinal disease, which could affect drug absorption.
- Intolerance to venipuncture
- Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
- Institutionalized volunteers.
- Used any prescribed medications (including monoamine oxidase inhibitors) within 14 days prior to the first dose of study medication.
- Used any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
- Used grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
- Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), recreational drugs, alcohol or other alcohol containing products within 48 hours prior to the first dose of study medication.
- Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
- Volunteer had clinically significant ECG abnormalities.
- Volunteer had sitting systolic blood pressure less than 100 mmHg or greater than 140 mmHg or sitting diastolic blood pressure less than 60 mmHg or greater than 90 mmHg and pulse rate less than 60 or greater than 100 per minute during screening.
- Volunteer had history of Hyperthyroidism or thyrotoxicosis.
- Volunteer had history of Glaucoma.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Label, Randomized, Two-period, Two-treatment, Two-sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study in Healthy Adult Human Subjects Under Fasting Conditions.
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.
- Being tested
- Lisdexamfetamine capsule, Elvanse® (Lisdexamfetamine dimesylate capsules, hard)
- Medical subject headings
- Attention Deficit Disorder with Hyperactivity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lisdexamfetamine capsuleDrug
Lisdexamfetamine 70 mg capsule
Elvanse® (Lisdexamfetamine dimesylate capsules, hard)Drug
Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard)
| Study group | Role | What they receive |
|---|---|---|
| Lisdexamfetamine capsule | Experimental | Lisdexamfetamine 70 mg capsule Receives: Drug: Lisdexamfetamine capsule; Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard) |
| Elvanse® (Lisdexamfetamine dimesylate capsules, hard) | Active comparator | Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard) Receives: Drug: Lisdexamfetamine capsule; Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Maximum measured plasma concentration (Cmax)
90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for Cmax
Measured: 72 hours
Area under the plasma concentration versus time curve from the zero time point to the last quantifiable concentration (AUCt)
90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for AUCt
Measured: 72 hours
Secondary outcomes (2)
The area under the plasma concentration versus time curve from zero to infinity (AUCi)
Descriptive Statistics
Measured: 72 hours
Time of the maximum measured plasma concentration (Tmax)
Descriptive Statistics
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Aug 2025
- Study start26 May 2025
- Primary completion6 Jun 2025
- Study completion17 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Attention Deficit/Hyperactivity Disorder (ADHD)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 48 participants (actual)
Sponsor and investigators
- Lead sponsor
- Humanis Saglık Anonim Sirketi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07098585
- Sponsor's protocol ID
- C1B05273
- Status last verified
- Jul 2025
- First submitted
- 25 Jul 2025
- Last updated
- 1 Aug 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Aug 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label, Randomized, Two-period, Two-treatment, Two-sequence, Crossover, Balanced, Single Dose Oral Bioequivalence Study in Healthy Adult Human Subjects Under Fasting Conditions.
- ClinicalTrials.gov ID
- NCT07098585
- Acronym / sponsor ID
- C1B05273
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 48 participants (actual)
- Lead sponsor
- Humanis Saglık Anonim SirketiIndustry (pharma, biotech, devices)
- Study start
- 26 May 2025 (actual)
- Primary completion
- 6 Jun 2025 (actual)
- Study completion
- 17 Jul 2025 (actual)
- First posted
- 1 Aug 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An open label, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single dose oral bioequivalence study in healthy adult human subjects under fasting conditions.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lisdexamfetamine capsule | Experimental | Drug: Lisdexamfetamine capsule, Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard)Lisdexamfetamine 70 mg capsule |
| Elvanse® (Lisdexamfetamine dimesylate capsules, hard) | Active comparator | Drug: Lisdexamfetamine capsule, Drug: Elvanse® (Lisdexamfetamine dimesylate capsules, hard)Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard) |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (11 listed)
- Age: 18 to 55 years old, both inclusive.
- Gender: Male and/or non-pregnant, non-lactating female.
- Female of child-bearing potential had a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days of the first dose of study medication. They used an acceptable form of contraception. For female of child-bearing potential, acceptable forms of contraception included the following:
- Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or ii. Barrier methods containing or used in conjunction with a spermicidal agent, or iii. Surgical sterilization or iv. Practicing sexual abstinence throughout the course of the study.
- Female was not considered of child-bearing potential if one of the following was reported and documented on the medical history:
Key exclusion criteria (26 listed)
- History of allergic responses to Lisdexamfetamine Dimesylate, sympathomimetic amines or other related drugs, or any of its formulation ingredients.
- Had significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, ECG recording, echocardiography, gynecological history and examination (including pelvic examination and routine breast examination) (for female volunteers)].
- Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoietic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
- History or presence of bronchial asthma.
- Used any hormone replacement therapy within 3 months prior to the first dose of study medication.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lisdexamfetamine capsuleLisdexamfetamine 70 mg capsule | Drug | Elvanse® (Lisdexamfetamine dimesylate capsules, hard), Lisdexamfetamine capsule |
| Elvanse® (Lisdexamfetamine dimesylate capsules, hard)Elvanse® (Lisdexamfetamine dimesylate 70 mg capsules, hard) | Drug | Elvanse® (Lisdexamfetamine dimesylate capsules, hard), Lisdexamfetamine capsule |
Primary outcome
Maximum measured plasma concentration (Cmax)
Time frame: 72 hours
90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for Cmax
Area under the plasma concentration versus time curve from the zero time point to the last quantifiable concentration (AUCt)
Time frame: 72 hours
90% confidence intervals for the geometric least squares mean ratio of (T/R) will be calculated and reported for AUCt
2 secondary outcomes
The area under the plasma concentration versus time curve from zero to infinity (AUCi)
Time frame: 72 hours
Time of the maximum measured plasma concentration (Tmax)
Time frame: 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Aug 2025.
Related trials for Attention Deficit/Hyperactivity Disorder (ADHD)
Enrolling by invitationPhase 3
An Open-Label Study to Assess the Long-Term Safety of Solriamfetol in Children and Adolescents With ADHD
ADHD
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingObservational study
Augmenting Parent Management Training for Child Temper Outbursts Using a Digital Tool
Disruptive Behavior Disorders, Conduct Disorder
Recruiting
Micronutrient Supplementation and Chronotherapy in Children With ADHD
Attention Deficit Hyperactivity Disorder (ADHD)
RecruitingPhase 3
Forward Treatment of Attention Deficit and Hyperactivity Using Solriamfetol (FOCUS-2)
ADHD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Lisdexamfetamine capsule and Elvanse® (Lisdexamfetamine dimesylate capsules, hard) in people with Attention Deficit/Hyperactivity Disorder (ADHD), run by Humanis Saglık Anonim Sirketi at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Maximum measured plasma concentration (Cmax) (time frame: 72 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2025.